Breast Cancer Clinical Trial
Official title:
A Non-Randomised Phase II Study to Evaluate the Optimal Uptake Time of 68GA-OPS202 as a sstr2 Positive PET Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as
a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor
subtype 2 (SSTR2) positive lesions.
68Ga-OPS202 is a radiolabelled imaging agent to be used in association with PET. 68Ga-OPS202
is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds
to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2)
Gallium 68, a radioisotope that, combined with OPS202, can be seen in the PET scanner.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03095352 -
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
|
||
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT03667716 -
COM701 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03709134 -
Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
|
||
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01857193 -
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Recruiting |
NCT03432429 -
REI-EXCISE iKnife Study
|
N/A | |
| Active, not recruiting |
NCT02139358 -
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03615573 -
Survey Study: Financial Impact of Breast Cancer Treatment
|
||
| Completed |
NCT03323333 -
Psychosocial Intervention Pilot for Partners in BRCA Testing
|
N/A | |
| Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
| Recruiting |
NCT03473639 -
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
|
Phase 1 | |
| Withdrawn |
NCT03285607 -
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT03530696 -
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03661892 -
Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets
|
Early Phase 1 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT01992432 -
Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
|
